Atogepant Reduces Psychological Dependence on Acute Treatments Evaluated With the Leeds Dependence Questionnaire: A Prospective Study
Abstract
BACKGROUND: The Leeds Dependence Questionnaire (LDQ) is a validated tool for assessing psychological dependence across various substances and has been adapted for use in headache patients. No study has yet explored the effects of preventive anti-CGRP treatments like atogepant on psychological dependence related to acute migraine medications.
METHODS: We conducted a prospective, real-world, single-center study on patients with migraine who were treated with atogepant 60 mg daily for 12 weeks. LDQ scores were assessed at baseline and after 12 weeks. Monthly headache days (MHDs), acute medication use, and presence of psychiatric comorbidities were collected. A linear mixed-effects model evaluated the effect of treatment over time, adjusting for medication overuse (MO) status and psychiatric comorbidities.
RESULTS: We included 43 patients (69.8% with chronic migraine, 67.4% with MO). The LDQ total score significantly decreased from 7.95 ± 5.79 to 6.42 ± 5.08 after treatment (mean difference: -1.53, p = 0.032). Significant improvements were seen in three specific LDQ items reflecting loss of control, compulsive use, and psychological distress. No significant correlation was found between the reduction in LDQ score and the change in acute medication use. Mixed-effects modeling confirmed a significant effect of treatment (p = 0.022), but independent of MO or MOH status or psychiatric comorbidities.
CONCLUSION: Preventive treatment with atogepant is associated with a significant…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 43 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.